Jan 13, 2017 by Brian FeroldiWill 2017 Be Illumina's Best Year Yet?Here are three reasons to believe that the genomic-sequencing giant is poised to have a prosperous 2017.
Jan 13, 2017 by Brian FeroldiHere's Why Insulet Corporation Rose by Double-Digits TodayShares jumped after one of the company's partners reported good news.
Jan 11, 2017 by Brian FeroldiHere's Why Novadaq Technologies Inc. Is Tanking TodayThe combination of weak fourth-quarter financial results and disappointing guidance caused shares to slump.
Jan 11, 2017 by Brian FeroldiWhy Novartis Dropped 15.1% in 2016Here's a look at why shareholders in the Swiss pharma giant had to suffer through a double-digit decline last year.
Jan 10, 2017 by Brian FeroldiWhy Agios Pharmaceuticals Sank 34.4% in 2016It was a roller-coaster year for investors in the clinical-stage biotech. Here's a review of the year's key headlines that caused shares to drop.
Jan 10, 2017 by Brian FeroldiHere's Why Illumina Is Soaring TodayShares rally in response to a number of exciting announcements that were made at the 2017 J.P. Morgan Healthcare Conference.
Jan 10, 2017 by Brian Feroldi, Dan Caplinger, Daniel Miller, and Matt DiLallo4 Cheap High-Yield Dividend Stocks You Don't Have to BabysitOn the hunt for a few high-yield stocks that won't keep you up at night? Our team of contributors thinks you should check out these four companies.
Jan 9, 2017 by Brian FeroldiWhy AMAG Pharmaceuticals, Inc. Is Falling TodayInvestors were hit with a barrage of news today. Here's a look at the key details that investors need to know.
Jan 9, 2017 by Brian FeroldiHere's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016It was an eventful year for the commercial-stage biotech. Let's take a closer look at the key events that caused the company's stock to get cut in half.
Jan 9, 2017 by Brian FeroldiWhy Aratana Therapeutics Inc. Rocketed 42.7% Higher in 2016Shares rose sharply in response to a series of positive announcements.
Jan 9, 2017 by Brian FeroldiHere's Why Insys Therapeutics Plummeted 67.2% in 2016It was a rotten year to be a shareholder of the pharmaceutical company. Here are the top reasons this pain medication specialist's shares headed for the bottom.
Jan 7, 2017 by Brian Feroldi 3 Companies Whose Sales Could Double in 2017These three stocks are primed for enormous growth in the year ahead.
Jan 7, 2017 by Brian FeroldiHere's Why Alnylam Pharmaceuticals Plunged 59.8% in 2016A major clinical setback removed a potential blockbuster drug from Alnylam's pipeline and led to a collapse in the company's share price.
Jan 6, 2017 by Brian FeroldiWhy Halozyme Therapeutics, Inc Fell 40.6% in 2016Shareholders took it on the chin, but the company continues to offer investors reasons to be optimistic.
Jan 5, 2017 by Brian FeroldiWhy CVS Health Stock Dropped 18.2% in 2016It was a rough year to be an investor in the retail pharmacy giant. Can the company get back on track in 2017?
Jan 5, 2017 by Brian FeroldiWhy Halozyme Therapeutics, Inc Is Rising TodayShares rise in response to a data release from an important Phase 2 study.
Jan 4, 2017 by Brian FeroldiThese 3 Dividend Stocks Are Ridiculously CheapScripts Network Interactive, Amgen, and Carnival are all dividend-paying stocks that trade at a sharp discount to the markets in general.
Jan 3, 2017 by Brian FeroldiHere's Why Inotek Pharmaceuticals Corp. Is Being ObliteratedShares plunge after the company reported phase 3 clinical results that missed the mark.
Dec 31, 2016 by Brian Feroldi10 Highest Dividend Yielding StocksLet's put these high-yielding stocks to the test to determine if any are actually worth owning.
Dec 28, 2016 by Brian Feroldi, Evan Niu, CFA, and Timothy Green3 Large-Cap Stocks to Buy in JanuaryFind out why our team of contributors think National Grid, IBM, and Facebook are compelling large-cap investments right now.
